Aram Zabeti , MD

Associate Professor of Neurology 
Director and Endowed Chair 
Waddell Center for Multiple Sclerosis

Undergrad & Medical Degree: Azad University School of Medicine 1999

Residency: West Virginia University School of Medicine 2012 (Neurology)

Fellowship: Oregon Health and Science University 2013 (Multiple Sclerosis)

American Board of Psychiatry and Neurology (Neurology) (Certification Date: 09-20-2012 )

Neurology

Aicardi Syndrome

Autoimmune Encephalitis

Behcet Syndrome (Neuro-Bechet)

Demyelinating Autoimmune Diseases, CNS

Demyelinating Disease

Devic's disease (Neuromyelitis optica)

Encephalitis

Encephalomyelitis

Limbic Encephalitis

Multiple Sclerosis (MS)

Myelin-Oligodendrocyte Glycoprotein

Myelitis

Neuromyelitis Optica Spectrucm Disorder (NMOSD)

Paraneoplastic Syndromes of the Nervous System

Primary Progressive Multiple Sclerosis (PPMS)

Relapsing-Remitting Multiple Sclerosis

Sarcoidosis (Neurosarcoidosis)

Secondary Progressive Multiple Sclerosis (SPMS)

Sjogrens Syndrome (Neuro-Sjogren)

Susac Syndrome

Systemic Lupus Syndrome (CNS-Lupus)

Transverse Myelitis

Neurology

Multiple Sclerosis
MS Specialist

Grant: #Medical Student Research Scholarship (Marcucci) Investigators:Marcucci, Samuel; Zabeti, Aram 06-02-2018 -06-01-2019 Foundation of the Consortium of Multiple Sclerosis Centers The Effect of Ocrelizumab on Lymphocytes in Multiple Sclerosis Patients Previously Exposed to Lymphocyte Depleting Agents Role:PI $5,000.00 Active Level:Private Non-Profit

Grant: #CCF / MS-1610-37047MS-1610-37047 Investigators:Zabeti, Aram 02-01-2018 -01-31-2023 Patient-Centered Outcomes Research Institute DELIVER-MS Role:PI $278,505.00 Awarded Level:Private Non-Profit

Grant: #FY20ITN345 / UM1AI109565 Investigators:Gul, Zartash; Zabeti, Aram 02-01-2020 -01-31-2021 National Institute of Allergy and Infectious Diseases Immune Tolerance Network - BEAT-MS Role:PI $485,483.00 Awarded Level:Federal

Grant: #17NS023 (108) Investigators:Zabeti, Aram 04-01-2019 -03-31-2024 Cleveland Clinic DELIVER-MS Role:PI 7500.00 Hold Level:Non Profit

Grant: #MN43964 08-01-2022 -07-31-2025 Genentech, Inc. A MULTICENTER, SINGLE-ARM, OPEN-LABEL, EXTENSION, ROLLOVER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS Role:PI 1866769.21 Hold Level:Industry

Grant: #MN43964 08-01-2022 -07-31-2025 Genentech, Inc. A MULTICENTER, SINGLE-ARM, OPEN-LABEL, EXTENSION, ROLLOVER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS Role:PI 1866769.21 Hold Level:Industry

Grant: #NMOSD-750 12-21-2022 -12-21-2025 CorEvitas, LLC CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) Role:PI 0.00 Hold Level:Industry

Grant: #NMOSD-750 12-21-2022 -12-21-2025 CorEvitas, LLC CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) Role:PI 0.00 Hold Level:Industry

Grant: #NMOSD-750 Investigators:Zabeti, Aram 03-14-2023 -03-14-2026 CorEvitas, LLC SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Neuromyelitis Optica Spectrum Disorder Registry (NMOSD-750) Role:PI 0.00 Hold Level:Industry

Grant: #MS-1610-37115 Investigators:Dragan, Elizabeth; Goldstick, Lawrence; Zabeti, Aram 04-12-2018 -11-01-2026 Patient-Centered Outcomes Research Institute TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial Role:PI 41824.70 Active Level:Non Profit

Grant: #WN43194 03-01-2022 -03-01-2025 Genentech, Inc. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION Role:PI 0.00 Hold Level:Industry

Grant: #WN43194 03-01-2022 -03-01-2025 Genentech, Inc. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION Role:PI 0.00 Hold Level:Industry

Grant: #JHU TREAT-MS_NMSS R-1902-33620 04-01-2019 -10-31-2024 National Multiple Sclerosis Society Traditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Role:PI 7560.01 Active Level:Non Profit

Grant: #JHU TREAT-MS_NMSS R-1902-33620 04-01-2019 -10-31-2024 National Multiple Sclerosis Society Traditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Role:PI 7560.01 Active Level:Non Profit

Grant: #400868 / OS00000659 / R01NS099068 Investigators:Zabeti, Aram 04-01-2023 -03-31-2028 Cincinnati Children's Hospital Medical Center Binding of Epstein Barr Virus EBNA2 unifies multiple sclerosis genetic mechanisms Role:PI 7769.00 Hold Level:Non Profit

Grant: #CCF; SI-2301-40767 07-01-2023 -09-30-2024 National Multiple Sclerosis Society Sprint-MS-2 Project Role:PI 18698.00 Hold Level:Non Profit

Grant: #CCF; SI-2301-40767 07-01-2023 -09-30-2024 National Multiple Sclerosis Society Sprint-MS-2 Project Role:PI 18698.00 Hold Level:Non Profit

Grant: #AI-1902-33619 Investigators:Zabeti, Aram 07-01-2023 -06-30-2026 National Multiple Sclerosis Society Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS LTE) Role:PI 11904.00 Hold Level:Non Profit

12-18-2023 -12-28-2026 Sanofi US Services Inc. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis Role:PI 967067.49 Hold Level:Industry

12-18-2023 -12-28-2026 Sanofi US Services Inc. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis Role:PI 967067.49 Hold Level:Industry

Grant: #WO_2023_025074 12-18-2023 -12-31-2026 Sanofi US Services Inc. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Fo Role:PI 664263.65 Hold Level:Industry

Grant: #WO_2023_025074 12-18-2023 -12-31-2026 Sanofi US Services Inc. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Fo Role:PI 664263.65 Hold Level:Industry

Peer Reviewed Publications

Kitsou, Efstathia; Pan, Sheng; Zhang, Jianpeng; Shi, Min; Zabeti, Aram; Dickson, Dennis W; Albin, Roger; Gearing, Marla; Kashima, Daniel T; Wang, Yan; Beyer, Richard P; Zhou, Yong; Pan, Catherine; Caudle, W Michael; Zhang, Jing (2008. ) Identification of proteins in human substantia nigra.Proteomics. Clinical applications, , 2 (5 ) ,776-82 More Information

Costa-Mallen, Paola; Checkoway, Harvey; Zabeti, Aram; Edenfield, Michael J; Swanson, Phillip D; Longstreth, W T; Franklin, Gary M; Smith-Weller, Terri; Sadrzadeh, Sayed M H (2008. ) The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , 147B (2 ) ,216-22 More Information

Obeidat, Ahmed Z; Jacob, Cara; Zabeti, Aram (2017. ) Concurrent Dawson's Fingers and Area Postrema Lesion in a Mixed Neuroimmune Disorder.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, , 44 (4 ) ,452-454 More Information

Fox, Robert J; Coffey, Christopher S; Cudkowicz, Merit E; Gleason, Trevis; Goodman, Andrew; Klawiter, Eric C; Matsuda, Kazuko; McGovern, Michelle; Conwit, Robin; Naismith, Robert; Ashokkumar, Akshata; Bermel, Robert; Ecklund, Dixie; Koepp, Maxine; Long, Jeffrey; Natarajan, Sneha; Ramachandran, Srividya; Skaramagas, Thomai; Thornell, Brenda; Yankey, Jon; Agius, Mark; Bashir, Khurram; Cohen, Bruce; Coyle, Patricia; Delgado, Silvia; Dewitt, Dana; Flores, Angela; Giesser, Barbara; Goldman, Myla; Jubelt, Burk; Lava, Neil; Lynch, Sharon; Miravalle, Augusto; Moses, Harold; Ontaneda, Daniel; Perumal, Jai; Racke, Michael; Repovic, Pavle; Riley, Claire; Severson, Christopher; Shinnar, Shlomo; Suski, Valerie; Weinstock-Gutman, Bianca; Yadav, Vijayshree; Zabeti, Aram (2016. ) Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.Contemporary clinical trials, , 50 ,166-77 More Information

Van Sanford, Carson; Obeidat, Ahmed Z; Hagen, Matthew; Zabeti, Aram (2019. ) A case of fatal invasive aspergillosis in a patient with neurosarcoidosis treated with infliximab.The International journal of neuroscience, , 129 (6 ) ,619-622 More Information

Fox, Robert J; Coffey, Christopher S; Conwit, Robin; Cudkowicz, Merit E; Gleason, Trevis; Goodman, Andrew; Klawiter, Eric C; Matsuda, Kazuko; McGovern, Michelle; Naismith, Robert T; Ashokkumar, Akshata; Barnes, Janel; Ecklund, Dixie; Klingner, Elizabeth; Koepp, Maxine; Long, Jeffrey D; Natarajan, Sneha; Thornell, Brenda; Yankey, Jon; Bermel, Robert A; Debbins, Josef P; Huang, Xuemei; Jagodnik, Patricia; Lowe, Mark J; Nakamura, Kunio; Narayanan, Sridar; Sakaie, Ken E; Thoomukuntla, Bhaskar; Zhou, Xiaopeng; Krieger, Stephen; Alvarez, Enrique; Apperson, Michelle; Bashir, Khurram; Cohen, Bruce A; Coyle, Patricia K; Delgado, Silvia; Dewitt, L Dana; Flores, Angela; Giesser, Barbara S; Goldman, Myla D; Jubelt, Burk; Lava, Neil; Lynch, Sharon G; Moses, Harold; Ontaneda, Daniel; Perumal, Jai S; Racke, Michael; Repovic, Pavle; Riley, Claire S; Severson, Christopher; Shinnar, Shlomo; Suski, Valerie; Weinstock-Guttman, Bianca; Yadav, Vijayshree; Zabeti, Aram (2018. ) Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.The New England journal of medicine, , 379 (9 ) ,846-855 More Information

Academic - Stetson Building
Cincinnati  Ohio, 45219
Phone: 513-558-0192
aram.zabeti@uc.edu